Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Income from Continuing Operations (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Income from Continuing Operations data on record, last reported at 38348000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 45.09% year-over-year to 38348000.0; the TTM value through Sep 2025 reached 40364000.0, up 138.26%, while the annual FY2024 figure was 88734000.0, 15.38% up from the prior year.
  • Income from Continuing Operations reached 38348000.0 in Q3 2025 per STOK's latest filing, down from 23482000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 112879000.0 in Q1 2025 and bottomed at 38348000.0 in Q3 2025.
  • Average Income from Continuing Operations over 4 years is 16282200.0, with a median of 25695000.0 recorded in 2024.
  • The widest YoY moves for Income from Continuing Operations: up 527.99% in 2025, down 45.09% in 2025.
  • A 4-year view of Income from Continuing Operations shows it stood at 25697000.0 in 2022, then dropped by 5.07% to 26999000.0 in 2023, then surged by 60.42% to 10685000.0 in 2024, then crashed by 258.9% to 38348000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 38348000.0 in Q3 2025, 23482000.0 in Q2 2025, and 112879000.0 in Q1 2025.